Related references
Note: Only part of the references are listed.An Antibody Directed against the Fusion Peptide of Junin Virus Envelope Glycoprotein GPC Inhibits pH-Induced Membrane Fusion
Joanne York et al.
JOURNAL OF VIROLOGY (2010)
Elevation of Intact and Proteolytic Fragments of Acute Phase Proteins Constitutes the Earliest Systemic Antiviral Response in HIV-1 Infection
Holger B. Kramer et al.
PLOS PATHOGENS (2010)
Maraviroc: A coreceptor CCR5 antagonist for management of HIV infection
Raymond Yost et al.
AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY (2009)
Maraviroc: a new CCR5 antagonist
Shilpa Sayana et al.
EXPERT REVIEW OF ANTI-INFECTIVE THERAPY (2009)
Monoclonal Antibodies against the Fusion Peptide of Hemagglutinin Protect Mice from Lethal Influenza A Virus H5N1 Infection
Nayana Prabhu et al.
JOURNAL OF VIROLOGY (2009)
The fusion inhibitor enfuvirtide in recent antiretroviral strategies
Alain Makinson et al.
CURRENT OPINION IN HIV AND AIDS (2009)
Structures and Mechanisms of Viral Membrane Fusion Proteins: Multiple Variations on a Common Theme
Judith M. White et al.
CRITICAL REVIEWS IN BIOCHEMISTRY AND MOLECULAR BIOLOGY (2008)
CgNa, a type I toxin from the giant Caribbean sea anemone Condylactis gigantea shows structural similarities to both type I and II toxins, as well as distinctive structural and functional properties
Emilio Salceda et al.
BIOCHEMICAL JOURNAL (2007)
Discovery and optimization of a natural HIV-1 entry inhibitor targeting the gp41 fusion peptide
Jan Muench et al.
CELL (2007)
Efficacy of short-term monotherapy with maraviroc, a new CCR5 antagonist, in patients infected with HIV-1
G Fätkenheuer et al.
NATURE MEDICINE (2005)
TMC114/ritonavir substitution for protease inhibitor(s) in a non-suppressive antiretroviral regimen:: a 14-day proof-of-principle trial
K Arastéh et al.
AIDS (2005)
Engineering chemokines to develop optimized HIV inhibitors
O Hartley et al.
CURRENT PROTEIN & PEPTIDE SCIENCE (2005)
T-1249 retains potent antiretroviral activity in patients who had experienced virological failure while on an enfuvirtide-containing treatment regimen
JP Lalezari et al.
JOURNAL OF INFECTIOUS DISEASES (2005)
Resistance to enfuvirtide, the first HIV fusion inhibitor
ML Greenberg et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2004)
The search for the CD8(+) cell anti-HIV factor (CAF)
JA Levy
TRENDS IN IMMUNOLOGY (2003)
Nef enhances human immunodeficiency virus type 1 infectivity and replication independently of viral coreceptor tropism
A Papkalla et al.
JOURNAL OF VIROLOGY (2002)
Emergence of resistant human immunodeficiency virus type 1 in patients receiving fusion inhibitor (T-20) monotherapy
XP Wei et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2002)
Share Paper
